Insmed Shares Tumble Amid Higher 1Q Expenses

Dow Jones05-08 03:51

By Christopher Kuo

Insmed shares tumbled after the company reported higher operating expenses in its latest quarter.

Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date.

The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share.

Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million.

The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said.

The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 07, 2026 15:51 ET (19:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633175694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 03:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633175694","market":"hk","top_or_hot":-1,"title":"Insmed Shares Tumble Amid Higher 1Q Expenses","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INSM\">Insmed</a> shares tumbled after the company reported higher operating expenses in its latest quarter. \n</p>\n<p>\n  Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date. \n</p>\n<p>\n  The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share. \n</p>\n<p>\n  Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million. \n</p>\n<p>\n  The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said. \n</p>\n<p>\n  The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 15:51 ET (19:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Shares Tumble Amid Higher 1Q Expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Shares Tumble Amid Higher 1Q Expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-08 03:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/INSM\">Insmed</a> shares tumbled after the company reported higher operating expenses in its latest quarter. \n</p>\n<p>\n  Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date. \n</p>\n<p>\n  The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share. \n</p>\n<p>\n  Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million. \n</p>\n<p>\n  The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said. \n</p>\n<p>\n  The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 15:51 ET (19:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633175694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633175694","pubTimestamp":1778183460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Insmed shares tumbled after the company reported higher operating expenses in its latest quarter.Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date.The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share.Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million.The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said.The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Insmed股价因第一季度支出增加而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nInsmed shares tumbled after the company reported higher operating expenses in its latest quarter. \n\n\n  Shares of the biopharmaceutical company fell 20% on Thursday to $109.19. The stock is down 37% year to date. \n\n\n  The company posted a loss of $163.6 million, or 76 cents a share, compared with a loss of $256.6 million, or $1.42 a share, a year earlier. Analysts polled by FactSet expected a loss of 96 cents a share. \n\n\n  Revenue rose to $306 million from $92.8 million a year earlier. Analysts expected revenue of $300.8 million. \n\n\n  The company's revenue from Arikayce treatment for lung disease rose 6% year over year. This was lower than analysts expected, according to Mizuho analysts. The company also reported lower Brinsupri new patient starts, the analysts said. \n\n\n  The company's operating expenses climbed. Selling, general and administrative expenses were $247.3 million, compared with $147.5 million a year earlier. Research and development expenses rose to $209.5 million from $152.6 million a year earlier. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 15:51 ET (19:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633175694","isCrawlerRequest":true}